HIGHLIGHTS
- who: Raja Dhar and collaborators from the Department of Pulmonology, The Calcutta Medical Research Institute, Kolkata, India have published the Article: ICS/Ultra LABA in the Treatment of Obstructive Airway Diseases: A Consensus of Indian Experts, in the Journal: (JOURNAL) of 31/08/2021
- what: The trial showed that triple therapy offered significant mortality benefits as compared to LABA/LAMA (HR=0.58).
- how: The SUMMIT trial was conducted in patients with moderate COPD and heightened cardiovascular disease risk showed that all-cause mortality with FF/Vi was 12.2% lower as compared . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.